Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced positive progress in the Phase 1 clinical trial of its immuno-stimulating STAT3 inhibitor, WP1066, with initial results showing bioavailability of the drug in patients.
Although this data is preliminary, it represents a significant milestone for the development of WP1066, commented Dr. Donald Picker, Moleculins Chief Science Officer. In the first two cohorts of the Phase 1 study, we are already seeing measurable levels of the drug in the patients plasma resulting from oral administration. Knowing we can deliver drug this way opens the door for further development and expanded clinical activity.
Walter Klemp, Moleculins Chairman and CEO added, We believe WP1066 is a first-in-class compound capable of stimulating a natural immune response in animal models while directly attacking tumors by modulating transcriptional activity and repressing what we call oncogenic transcription factors. Chief among these is STAT3, considered a master regulator of tumor progression. While activity in animal models has been very promising, one of the goals of this trial was to determine the potential for bioavailability in humans. The initial positive indications of this clinical trial increase our confidence that WP1066 has the potential to become an important drug in the treatment of certain cancers. The initial demonstration of human bioavilability is an important milestone.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.